Drug Delivery Technology

3M Drug Delivery Systems has been a major supplier of metered-dose inhaler valves and canisters for more than 50 years. As the developers of the first CFC-free MDI, we are experienced at overcoming the challenges that designing components for use with CFC-free propellants presents. 3M is the only MDI component supplier that manufactures both valves and canisters, allowing optimization of these components simultaneously, ensuring compatibility, while delivering the convenience of a single source. For more information, contact 3M Drug Delivery Systems at (800) 643-8086 or visit www.3M.com/dds.

Aveva has numerous products for license from its development pipeline along with a full compliment of R&D capabilities to produce transdermal drug delivery systems that fortify R&D pipelines and maximize product life cycles. Aveva Drug Delivery Systems is one of the world’s largest manufacturers of and a pioneer in transdermal drug delivery systems of providing pharmaceutical partners with fully integrated, controlled-release transdermal products that fulfill unmet market needs. Products for licensing include Sufentanil, Fentanyl, Clonidine, and Nicotine. For more information, contact Robert Bloder, VP of Business Development, at (954) 624-1374 or visit www.avevadds.com.

Azaya Therapeutic’s Protein Stabilized Liposome (PSL^TM) nanotechnology utilizes a new, next-generation nanotechnology to produce liposome-encapsulated drug products. The company’s interest in these agents is based on the potential for improved delivery of poorly soluble drugs, reduction in chemical and enzymatic degradation, and improvement in the toxicity profile of an agent. This technology is a key advancement in liposomal delivery, utilizing a proprietary single-step manufacturing process that produces uniform particles less than 200 nanometers while stabilizing drug encapsulations. Enhanced delivery of cytotoxic agents using PSL nanotechnology provides a safer, less expensive, and more convenient use to preferentially target tumors through an enhanced permeation retention (EPR) effect. In addition, Azaya’s PSL nanotechnology offers an active targeting mechanism that utilizes protein identification of up-regulated tumor biomarkers. For more information, contact Azaya Therapeutics at (210) 341-6600 or visit www.azayatherapeutics.com.

Azopharma Product Development Group, The Total Product Development Company ^TM, is dedicated to providing clients with comprehensive product development services from discovery through commercialization. Azopharma maximizes communication and minimizes downtime by bundling services from key sections of the drug development process, including the Preclinical, CMC, and Clinical phases. Our capabilities include Full NCE Development, Full IND Development, Full NDA Development, Full ANDA Development, and Full Medical Device Development. Whether it’s a stand-alone service or a comprehensive program, Azopharma has the solution to fit your needs! Our group of companies includes Azopharma Contract Pharmaceutical Services, AniClin Preclinical Services, and AvivoClin Clinical Services. For more information, contact Azopharma Product Development Group at (954) 433-7480, development@azopdogroup.com, or visit www.azopodogroup.com.